78 results about "Intestinal bacteria" patented technology

The invention discloses an intestinal bacterial composition for improving a cognitive function and relieving neuroinflammation and an application of the intestinal bacterial composition, and belongs to the technical field of biomedicine and microbiology, the intestinal bacterial composition is composed of a Lachnospiraceae bacterium, a Bacteroides multiforme and a Roseburiatestinae bacterium, and the intestinal bacterial composition is prepared from the following raw materials of the following raw materials of the intestinal bacterial composition: the Lachnospiraceae bacterium, the Bacteroides multiforme and the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium, the Roseburiatestinae bacterium and the like. Experimental research results show that a modular synergistic effect exists among the helicobacter hirsuticus, the bacteroides multiforme and the Roche enterobacter, and the pharmaceutical composition has a remarkable neuroprotective effect on a cognitive impairment mouse model and an Alzheimer disease mouse model, can improve the cognitive function and relieve neuroinflammation, and can be used for preparing a neuroprotective agent for treating the cognitive impairment mouse model and the Alzheimer disease mouse model. A new thought and method can be provided for treatment of cognitive impairment related diseases and neuroinflammation related diseases.

The invention relates to a gastric acid-resistant sustained-release intestinal bacteria capsule based on bionic mucous membrane-enzymolysis response and a preparation method thereof. The gastric acid-resistant sustained-release intestinal bacteria capsule comprises a core layer, an adhesive layer, an outer-layer composite film and a protective coating from inside to outside, the core layer consists of intestinal flora and a multifunctional freeze-drying protective agent; the adhesive layer is composed of trehalose, N-acetyl glucosamine and MUC2 recombinant protein; the outer-layer composite film is composed of a base material and a functional filler; the protective coating is composed of beewax and chitosan. The anti-gastric acid sustained-release intestinal bacteria capsule based on bionic mucosa-enzymolysis response provided by the invention has excellent gastric acid resistance, and the gastric acid resistance is remarkably improved; good slow release performance is achieved, and accurate slow release of enzymatic hydrolysis response can be achieved; the colonization efficiency of the intestinal bacteria can be effectively improved; the storage stability is good. The preparation method provided by the invention has the advantages of simplified steps, short time consumption, controllable core operation time and obviously shortened whole process, and is beneficial to keeping the activity of the flora.

The invention relates to the technical field of comprehensive treatment of agricultural pests, and particularly provides a bactrocera cucurbitae double-trapping type attractant based on optimal matching of host and intestinal bacteria volatile matters and application of the bactrocera cucurbitae double-trapping type attractant. The attractant comprises an active component and a synergistic component, the active component is derived from balsam pear and towel gourd volatile matters and bactrocera cucurbitae intestinal bacterial metabolites, and comprises 2-methyl ethyl valerate, propyl hexanoate, ethyl hexadienoate, heptanal, benzyl alcohol, 3-methyl acetic acid-1-butanol, indole and 1-undecanol; and the synergistic component is myzobenzoic ketone. Active components are quickly released in the early stage of application, so that the attraction efficiency is remarkably improved; the synergistic component prolongs the trapping lasting period through the slow release effect, and the long-term trapping effect is ensured. All the components of the attractant provided by the invention are biological sources or environment-friendly chemical substances, the attractant meets the requirement of green prevention and control, can efficiently attract male and female adults at the same time, makes up the limitation that a traditional sex attractant only induces male adults or a food attractant only induces female adults, and is beneficial to more comprehensive control of population quantity.

The utility model relates to the technical field of culture medium shunting, in particular to an intestinal bacterium enrichment liquid culture medium self-flowing racking machine which is characterized in that when the racking machine is used, a plurality of groups of culture bottles are respectively placed on a bottle carrying assembly, and then the bottle carrying assembly is placed on a supporting table and is positioned and fixed through two groups of positioning assemblies; then liquid adding operation is conducted on the multiple sets of culture bottles through the flow dividing assembly, after liquid adding is completed, a worker integrally moves the multiple sets of culture bottles through the bottle carrying assembly, then the other set of bottle carrying assembly is placed and positioned, and the liquid adding efficiency is improved; comprising a supporting table, supporting legs and a liquid storage tank, the multiple sets of supporting legs are arranged at the bottom end of the supporting table, the liquid storage tank is installed at the top end of the supporting table, the distribution assembly is arranged at the output end of the liquid storage tank, the bottle carrying assembly is used for transferring multiple sets of culture bottles, and the two sets of positioning assemblies are symmetrically arranged at the top end of the supporting table.

This invention provides a multi-omics diagnostic model for inflammatory bowel disease (IBD), along with its biomarker screening method, applications, and reagent kits. Currently, there is no gold standard for diagnosing IBD, leading to many unidentifiable suspected cases in clinical practice. This invention utilizes information on the abundance of gut bacteria, the functional genes of gut bacteria, and the content of intestinal metabolites to establish a predictive model for IBD. Furthermore, this invention integrates the above two types of omics information and the prediction across three information dimensions to establish a predictive model with impressive predictive capabilities. The method and model of this invention can assist in the diagnosis and differentiation of IBD.

The invention relates to the technical field of biological medicines, in particular to application of intestinal probiotics and metabolites thereof in treating autism spectrum disorders. According to the application disclosed by the invention, six intestinal bacteria which are in causal negative correlation with ASD are identified for the first time from the perspective of genetics, and the effects of ruminococcus gavreuii of the ruminococcus and the effects of Satasella wadsworensis of the ruminococcus on the autism spectrum disorder are verified. The invention also discloses a kit for detecting the autism spectrum disorder of the Autism spectrum disorder and a kit for detecting the autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder of the Autism spectrum disorder. Experiments prove that the traditional Chinese medicine composition can significantly improve social defects of model mice and has no side effects on normal mice. The invention provides new targets and candidate substances for developing probiotic preparations, metabolite supplements or functional foods for preventing, relieving or treating ASD, and has important clinical application prospects.

This invention discloses a method for the synergistic metabolic analysis of multiple components of traditional Chinese medicine (TCM) integrated with the gut microbiota. After initializing the microbiota ecosystem, a solution of multi-component TCM extracts is continuously injected into a microfluidic chip. Stable isotope-labeled precursors are pulsed into a specific simulation region to perform spatial isotope encoding. A standing wave acoustic field is applied at the sampling node of the microfluidic chip, and multiphase fluid spatial splitting is performed using the difference in the primary acoustic radiation force experienced by the particles to derive cell-free TCM metabolites. The cell-free TCM metabolites are separated by chromatography and gas phase drift separation. A four-dimensional metabolic feature array is constructed, and the absolute value of the mass shift is calculated for spatial inverse decoding. Closed-loop feedback is triggered based on the rate of change of target metabolite ion abundance, increasing the amplitude of the standing wave acoustic field pressure to confine intestinal bacteria and performing in-situ enrichment of synergistic metabolic intermediates. This invention realizes the spatial metabolic trajectory tracing and network reconstruction of multiple components of TCM in a complex gut microbiota ecosystem.

A use of intestinal bacteria that co-produce D-lactate and a metabolite thereof D-lactate in predicting exercise capacity. The intestinal bacteria that co-produce D-lactate and the metabolite thereof D-lactate affect the levels of the exercise-related hormones dopamine and adrenaline, thereby significantly impairing exercise capacity. The intestinal bacteria that co-produce D-lactate and the metabolite thereof D-lactate are markers that can be used for routine exercise monitoring and for regulating exercise tolerance.

The present invention addresses the problem of: developing a method capable of noninvasively sampling and analyzing intestinal mucosa bacteria; analyzing the intestinal bacteria, especially intestinal mucosa bacteria on the basis of the method; and developing a therapeutic method for diseases occurring in the intestinal tract for which therapeutic methods have not been established.　The inventors of the present invention have found that bacteria contained in a cotton swab (swab) sample on the feces surface exhibit a bacterial flora composition similar to that of bacteria existing in the intestinal mucosa; and, as a result of analysis based on the finding, have clarified that Adlercreutzia, which has not been reported until now as a mucosa-related bacterium, lives in the large intestinal mucosa layer, produces taurine, which is a strong anti-inflammatory compound, by the action of the bile acid-deconjugating enzyme, and alleviates enteritis, thereby completing the present invention. In other words, the present invention can provide a composition having an anti-inflammatory effect, which includes a bacterium of the genus Adlercreutzia, or a bile acid-deconjugating enzyme that is derived from a bacterium of the genus Adlercreutzia.

The invention belongs to the technical field of bioengineering, and discloses a specific identification primer and method for lactobacillus curvatus in human intestinal tracts and application. The identification primer comprises an upstream primer COG3825F1 and a downstream primer COG3825R1, the nucleotide sequence of the upstream primer COG3825F1 is 5 '-GTCACAACAAGACCGATTT-3', and the nucleotide sequence of the downstream primer COG3825R1 is 5 '-CTGTTTCTACAACTTGTGCT-3', and the nucleotide sequence of the upstream primer COG3825F1 and the nucleotide sequence of the downstream primer COG3825R1 are 5 '-GTCACAACAAGACCGATTT-3'. The specific COG3825 gene of the lactobacillus flexus is screened to serve as a target sequence design primer, and PCR, gel electrophoresis and qPCR verification show that the primer has extremely high specificity and sensitivity and can accurately distinguish the lactobacillus flexus from the related lactobacillus and other common intestinal bacteria under the complex micro-ecological background of the human intestinal tract; the identification method based on the primer is easy and convenient to operate and accurate in result, qualitative and quantitative detection of the lactobacillus brevis in human intestinal samples, food samples and other environment samples can be achieved, and important technical support is provided for related research, application development and micro-ecological monitoring of the lactobacillus brevis.

The invention discloses a glycosyl hydrolase derived from intestinal bacteria and application of the glycosyl hydrolase. A glycosyl hydrolase gene for catalyzing trillioside to be hydrolyzed into diosgenin is cloned from intestinal microorganism enterococcus faecalis for the first time, and protein coded by the glycosyl hydrolase gene is identified as multifunctional glycosyl hydrolase; the diosgenin can be catalyzed to generate diosgenin, and the hydrolysis of other saponins such as steroid saponin and C3, C6 and C21 glycosyl of ginsenoside can be catalyzed, so that a basis is provided for the biological enzymolysis of the diosgenin and other saponins or sapogenin. Meanwhile, biological enzymolysis of the diosgenin makes up for the defects of high production cost, serious environmental pollution and the like of a traditional acid hydrolysis method, and the diosgenin has a great application prospect.

The invention discloses application of chlorogenic acid in preparation of a product with functions of protecting intestinal mucosa and regulating intestinal flora, and belongs to the technical field of medical health care products. Animal experiments prove that the chlorogenic acid can effectively relieve intestinal mucosa barrier damage caused by hypoxia, reverse abnormal increase of alpha-diversity of intestinal bacteria and optimize the flora structure in allusion to the fact that the regulation effect of the chlorogenic acid on the intestinal mucosa damage and intestinal flora disorder induced by hypoxia is not involved in the prior art. The product is suitable for preventing and treating intestinal mucosal barrier damage and intestinal microecological imbalance caused by acute and chronic hypoxia or drug stimulation.

The application belongs to the technical field of microorganisms, and provides a carogenic Enterobacter and application thereof in degrading solanum alkaloid. Enterobacter cancerogenus JLU1, which was preserved in the China General Microbiological Culture Collection Center on June 23, 2025, and has a preservation number of CGMCC No.34971. In the embodiment of the application, intestinal bacteria are separated by dissecting the tomato leafworm larva intestine, and then bacteria resistant to solanum alkaloid or even capable of degrading and utilizing solanum alkaloid are screened and identified, so that the role of the bacteria in the resistance of the tomato leafworm to solanum alkaloid is analyzed, and a foundation is laid for subsequent research on the resistance mechanism.

The invention discloses an intestinal bacterium-derived melatonin synthetase and an application thereof. Specifically, the melatonin synthetase is selected from one or more of a DDC enzyme, an AANAT enzyme and an AST enzyme, the DDC enzyme comprises an amino acid sequence as shown in SEQ ID NO.2 or an active fragment of the amino acid sequence, or an analogue of which the similarity with the amino acid sequence as shown in SEQ ID NO.2 is more than 80%, and the DDC enzyme comprises an amino acid sequence as shown in SEQ ID NO.2 or an active fragment of the amino acid sequence as shown in SEQ ID NO.2 or an analogue of which the similarity with the amino acid sequence as shown in SEQ ID NO.2 is more than 80%. The AANAT enzyme comprises an amino acid sequence as shown in SEQ ID NO.34 or an active fragment thereof, or an analogue of which the similarity with the amino acid sequence as shown in SEQ ID NO.34 is more than 80%, and the AST enzyme comprises an amino acid sequence as shown in SEQ ID NO.42 or an active fragment thereof, or an analogue of which the similarity with the amino acid sequence as shown in SEQ ID NO.42 is more than 80%. On one hand, the melatonin synthetase can be used for improving the melatonin level of a host and improving related diseases; on the other hand, the method can be used for biosynthesis of melatonin and has a good application prospect.

Provided in the present invention is an engineered bacterium, the engineered bacterium comprising an exogenous cyuP gene and / or cyuA gene, the exogenous cyuP gene encoding a cysteine transporter protein, the exogenous cyuA gene encoding a cysteine desulfurase, and the engineered bacterium being an intestinal bacterium or a probiotic.

This invention provides a composition comprising milk thistle extract and Akkella myxophilus. This composition can rapidly increase the abundance of Akkella myxophilus in the intestinal environment, promote its proliferation in the intestine, increase the variety and abundance of beneficial intestinal bacteria, colonize beneficial bacteria, and eliminate harmful bacteria. It has the effects of improving intestinal microecology, relieving fatigue, protecting the liver, reducing fat, relieving hangovers, anti-inflammatory, antioxidant, anti-aging, and beautifying the skin.

This invention relates to a strain of *Lactobacillus plantarum* with accession number 35817 from the China General Microbiological Culture Collection Center (CGMCC), and its application in improving intestinal immune function and promoting human intestinal health. This strain can be used as a probiotic ingredient to prepare compositions with the following functions: enhancing resistance to intestinal bacterial infections, maintaining intestinal barrier function, and regulating inflammatory responses. The compositions can be formulated into foods, beverages, or pharmaceuticals for enhancing intestinal immune function and intestinal health.

This invention provides an information processing device, an information processing method, and a computer program for determining an individual's immune response to probiotics. [Solution] In an information provision system in which a terminal device and an information provision device are connected to communicate via a network, and a judgment model generation device and an information provision device are connected to communicate via a network, the judgment model generation device 20, which is an information processing device, includes a control unit 23 that acquires immune information of a target person based on intestinal bacteria information, which is information about the intestinal bacteria of the target person, and an immune judgment model in which the intestinal bacteria information is an explanatory variable and immune information indicating the immune response of the target person to probiotics is an objective variable.

[PROBLEM] To provide a formulation that is safe for ingestion over a long period of time and can improve the enterobacterial flora or can enhance the barrier function of the intestinal mucosa.[SOLUTION] The present invention is an enteric capsule formulation for improving enterobacterial flora containing nicotinamide mononucleotide as an active ingredient.

This invention discloses a functional oligosaccharide syrup prepared using crystalline glucose mother liquor, belonging to the field of comprehensive utilization of crystalline glucose mother liquor. Using crystalline glucose mother liquor as a substrate, this invention prepares an oligosaccharide syrup mainly composed of gentiosaccharides and maltodextrins through a combination of glucosidase catalysis and yeast fermentation. In vitro fermentation experiments have demonstrated that it can significantly increase the content of short-chain fatty acids in the product and promote the proliferation of beneficial intestinal bacteria such as Bifidobacteria and Lactobacillus, showing potential as a novel prebiotic. The product of this invention has high added value, and the preparation process is simple, facilitating industrial application. It provides a green, low-carbon, and economically beneficial new method for the comprehensive utilization of crystalline glucose mother liquor.

The application discloses an intestinal microbial marker combination for cirrhosis diagnosis and application thereof, which is composed of 8 specific intestinal bacterial species. The application accurately identifies the core combination from 181 differential characteristics by performing metagenomic sequencing on fecal samples of cirrhosis patients and healthy controls, and combining random forest, LASSO regression and recursive feature elimination algorithms. The random forest diagnosis model based on the 8 markers realizes an excellent performance of area under curve (AUC) 0.841, sensitivity 84.3% and specificity 83.7% on a completely independent test set, and the performance does not decrease compared with the full feature model in the case of reducing the number of characteristics by 86.9%. The marker combination provided by the application is highly simplified and has strong discrimination, and provides a clear and efficient microbiological basis and technical scheme for developing a cirrhosis non-invasive diagnosis kit, a gene chip and other products based on intestinal flora.

A short-chain fatty acid production promoter containing gluconic acid derivatives that promotes the production of short-chain fatty acids by intestinal bacteria in the intestinal tract. [Solution] To provide a novel prebiotic material that promotes the production of short-chain fatty acids by intestinal bacteria.

The application relates to a nano enteric-targeting preparation for preventing and treating chicken intestinal bacterial diseases and a preparation method thereof, and belongs to the technical field of biological medicine preparation. The preparation method of the targeting preparation is as follows: polylactic acid-glycolic acid copolymer PLGA is taken as a carrier, drug components are added, and the drug components are mixed with polyethylene glycol PEG300 and Tween 80 to prepare a nano particle suspension liquid; after montmorillonite is added, further addition of acrylic resin II and preparation of an enteric layer are carried out to perform coating; after freeze-drying, probiotics are mixed to prepare a nano enteric-targeting preparation powder. In the application, the problem that drug components have an inhibiting effect on probiotics in the process of compounding microbial and traditional Chinese medicine active ingredients is effectively solved, the solubility of the drug components is improved, the targeting preparation forms a targeting effect on pathogenic bacteria in the intestinal tract, and the effect of synergistically preventing and treating multiple chicken intestinal bacterial diseases is improved.

This invention belongs to the field of biomedicine, specifically relating to a strain of Bifidobacterium bifidum and its application in eye health products. The Bifidobacterium bifidum (… Bifidobacterium bifidum Bifidobacterium bifidum BB00, with accession number CGMCC No. 34389, is a product of this invention. It can improve the clinical symptoms of dry eye syndrome, increase tear secretion, prolong tear film breakup time, reduce ocular surface disease index, alleviate corneal epithelial damage, and regulate palpebral fissure opening. It can also regulate the composition of the intestinal flora, increase flora diversity, and inhibit the growth of pathogenic intestinal bacteria. Bifidobacterium bifidum BB00 not only provides an innovative solution to the clinical pain point of dry eye syndrome, achieving synergistic intervention between intestinal regulation and eye health, but also possesses scientific innovation, clinical effectiveness, and industrialization potential. It has significant value for the application of bacteria and bacterial agents in the biomedical field and for the treatment of ocular surface-intestinal related diseases.

The invention relates to a nano enteric targeting preparation for preventing and treating chicken intestinal bacterial diseases and a preparation method thereof, and belongs to the technical field of biological medicine preparation.The preparation method of the targeting preparation comprises the steps that polylactic acid-glycolic acid copolymer PLGA serves as a carrier, medicine components are added and mixed with polyethylene glycol PEG300 and Tween 80 to prepare nanoparticle suspension, montmorillonite is added, and the nano enteric targeting preparation is prepared. And further adding acrylic resin II, preparing an enteric-coated layer for coating, freeze-drying, and mixing with probiotics to prepare nano enteric-coated targeted preparation powder. According to the invention, the problem that drug components have an inhibition effect on probiotics in the compounding process of microorganisms and active components of traditional Chinese medicines is effectively solved, the solubility of the drug components is improved, the targeting preparation has a targeting effect on pathogenic bacteria in intestinal tracts, and the effect of synergistic targeting prevention and treatment of various intestinal bacterial diseases of chickens is improved.

The present disclosure relates to a composition containing parsnip extract as an active ingredient which reduces the downregulation of tight junction protein expression, promote the proliferation of beneficial intestinal bacteria, improve the intestinal environment such as maintaining a slightly acidic intestinal environment, and have effects such as reducing intestinal permeability. Therefore, the composition may improve intestinal health and prevent, treat, or improve leaky gut syndrome, and may be used as a material for foods, feeds, pharmaceuticals, or quasi-drugs. Additionally, the composition may have body fat reduction and weight loss activities, reduce the protein expression of lipid metabolism-related factors such as ACC, FAS, SREBP1, ChREBP, G6PD, or C / EBPα, and have effects such as reducing liver weight, reducing blood sugar, reducing ALT or AST levels, reducing insulin resistance, and reducing extent of liver damage. Therefore, the composition may prevent, treat, or improve obesity or a metabolic disease.

This invention discloses the application of Jerusalem artichoke polysaccharide in the preparation of drugs for regulating intestinal flora, belonging to the field of intestinal flora drugs. The drugs for regulating intestinal flora use Jerusalem artichoke polysaccharide as the active ingredient. These drugs improve intestinal disorders by increasing the proliferation of beneficial intestinal bacteria and the content of short-chain fatty acids, metabolites of intestinal flora. The Jerusalem artichoke polysaccharide prepared by this invention contains uronic acid and pyranose, and is mainly composed of fructose and glucose, with an average molecular weight of 2228 Da. The preparation method of Jerusalem artichoke polysaccharide in this invention has high yield, low cost, and is suitable for industrial production.

The invention relates to the field of treatment of obesity through intestinal bacteria transplantation, in particular to a marker combination related to the curative effect of treating obesity through flora transplantation, a product and application of the marker combination and the product. The biomarker composition is prepared from bifidobacterium animalis, ruminococcus sp, bifidobacterium adolescentis, a delazobivibrio sp, a delazobivibrio sp, a Eubacter asiaticus, an enterococcus faecalis and a Citrobacter amalonatus, and the biomarker composition is prepared from the following raw materials: the bifidobacterium animalis, the ruminococcus sp, the bifidobacterium adolescentis, the delazobivibrio sp, the delazobivibrio sp, the Eubacter asiaticus, the Enterococcus faecalis and the Citrobacter amalonatus. The invention provides a reagent for detecting the marker combination, which can be used for preparing a product for predicting / evaluating the curative effect, and also provides a computer readable storage medium containing a storage curative effect judgment instruction, and a curative effect evaluation system containing a detection device and a comparison device. The association between the flora and the obesity curative effect is disclosed for the first time, the method is non-invasive and high in accuracy, the blank that the flora transplantation treatment obesity curative effect lacks a specific marker is filled, and a basis is provided for obesity diagnosis and treatment and individualized treatment.

The application provides an intestinal bacteria transplantation donor-recipient intelligent matching method and system based on multi-modal data, and relates to the technical field of biological medicine. The method comprises the following steps: collecting multi-modal data of a reaction body; constructing a microorganism network graph of each reaction body according to the multi-modal data, taking a microorganism population as a node and taking an interaction intensity between the microorganism populations determined based on a conditional dependence theory as an edge weight; extracting a topological feature vector of the microorganism network graph to quantify the microorganism population stability of the corresponding reaction body; combining the topological feature vectors of the donor and the recipient to establish a data-driven transplantation simulation model; solving a steady-state solution of the transplantation simulation model to obtain a steady-state topological feature vector of the recipient; combining the steady-state topological feature vector to calculate a matching index of the recipient and the donor; changing the donor and returning to re-collecting until all the donors are calculated, and outputting the recipient and the donor corresponding to the maximum matching index as a matching result. The stability and accuracy of the matching result are improved.

The invention discloses an application of a hispiraceae bacterium in preparation of a medicine for relieving the hepatotoxicity of saikoside D, and relates to the field of medicines. According to the invention, an intestinal bacterium with a specific antagonistic effect on the hepatotoxicity of saikoside D is identified and applied for the first time. The limitation that non-specific regulation is carried out through broad-spectrum probiotics or complex compounds traditionally is broken through, and the crossing from'macroscopic flora regulation 'to'key strain targeting' is realized. The strategy directly aims at a key link of SSd toxicity generation, the liver can be effectively protected, meanwhile, the core drug effect of SSd can be reserved to the maximum extent, and the final goal of toxicity reduction and effect storage is really achieved.